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ABSTRACT
Background. A limited number of studies have assessed health-
related quality of life (HRQoL) in autosomal dominant polycys-
tic kidney disease (ADPKD). Results to date have been conﬂict-
ing and studies have generally focused on patients with later
stages of the disease. This study aimed to assess HRQoL in
ADPKD across all stages of the disease, from patients with early
chronic kidney disease (CKD) to patients with end-stage renal
disease.
Methods. A study involving cross-sectional patient-reported
outcomes and retrospective clinical data was undertaken April–
December 2014 in Denmark, Finland, Norway and Sweden.
Patients were enrolled into four mutually exclusive stages of the
disease: CKD stages 1–3; CKD stages 4–5; transplant recipients;
and dialysis patients.
Results. Overall HRQoL was generally highest in patients with
CKD stages 1–3, followed by transplant recipients, patients with
CKD stages 4–5 and patients on dialysis. Progressive disease
predominately had an impact on physical health, whereas men-
tal health showed less variation between stages of the disease. A
substantial loss in quality of life was observed as patients pro-
gressed to CKD stages 4–5.
Conclusions. Later stages of ADPKD are associated with
reduced physical health. The value of early treatment interven-
tions that can delay progression of the disease should be
considered.
Keywords: ADPKD, chronic kidney disease, patient-reported
outcomes, polycystic kidney disease, quality of life
INTRODUCTION
Autosomal dominant polycystic kidney disease (ADPKD) is a
dominantly inherited systemic disease characterized by progressive
growth of renal cysts. Recent studies of European populations esti-
mate the prevalence rate in Europe at less than 4 in 10 000 [1, 2].
Kidney volume growth due to progressive cyst formation
and expansion precedes functional renal deterioration [as meas-
ured by glomerular filtration rate (GFR)] by several decades [3].
Clinical symptoms of renal disease can occur at any age but typ-
ically begin in the third or fourth decade of life. The severity of
manifestations related to the disease are heterogeneous and well
documented to include hypertension, pain, extrarenal cyst for-
mation, intracranial aneurysms, mitral valve prolapse and renal
failure [4]. Around 50% of patients require renal replacement
therapy due to kidney failure, which typically develops in the
fourth to sixth decade of life [3]. It is generally assumed that
ADPKD accounts for around 10% of patients who are depend-
ent on renal replacement therapy [5].
No patient-reported outcome measures are available that
fully capture the burden of symptoms reported by patients with
ADPKD. A recent literature review of patient perspectives of
living with ADPKD identified greater patient engagement in
pain management, counselling to reduce the burden of ‘genetic
guilt’ and specific family planning decision support tools as pri-
oritized health care interventions [6]. The review highlighted
that the unpredictable onset of volatile pain had a negative
impact on daily living and prevented patients from pursuing
long-term life goals.
VC The Author 2016. Published by Oxford University Press on behalf of ERA-
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|A handful of studies have assessed general health-related qual-
ity of life (HRQoL) in ADPKD. However, results to date have
been conflicting and studies have generally focused on patients
with later stages of the disease. A study of pre-dialysis patients
that used the validated Short Form-36 (SF-36) instrument found
no differences in HRQoL compared with the general US popula-
tion [7]. In addition, a subgroup analysis of patients with estab-
lished renal insufficiency (20 < GFR < 65 mL/min/1.73 m2)
found no differences compared with a renal disease population
with similar levels of renal function. Another study using the SF-
36 found significantly lower scores for ADPKD patients (49% of
whomwere on dialysis) compared with the general Japanese pop-
ulation [8]. The study also observed a difference between dialysis
and non-dialysis patients in terms of physical health, but not
mental health. An analysis of data from the HALT-PKD trial
showed that pain was common in patients with early disease
(GFR>60 mL/min/1.73 m2) [9]. Pain was however not related to
height-adjusted total kidney volume except at levels greater than
1000 mL/m. All SF-36 health domain scales, stratified by esti-
mated GFR (eGFR), were comparable to the age-matched general
US population. Finally, a recent cross-sectional study of ADPKD
patients not on dialysis in the UK revealed a high prevalence of
reduced quality of life and increased psychosocial risk with lower
eGFR and increased kidney size [10].
We present the first study of HRQoL in ADPKD that
includes all stages of the disease, from patients with early
chronic kidney disease (CKD) to patients on dialysis and trans-
plant recipients.
MATERIALS AND METHODS
Study design
We conducted a multi-site study involving cross-sectional
patient-reported outcomes (PROs) and retrospective clinical
data. Nine nephrology clinics participated in total; four in
Denmark, one in Finland, two in Norway and two in Sweden.
Between April and December 2014, we enrolled non-randomized
samples of subjects from each clinic. Resource constraints and the
rarity of the disease limited the recruitment target to 200 patients
evenly distributed across the stages of the disease. Patients were
recruited by phone or during a routine visit. Participation did not
result in a change in the standard of care.
Ethics approvals for the study were granted by the Helsinki
University Hospital Ethical Review Board, the Regional
Committee of Medical and Health Research Ethics in Oslo (REC
South East) and the Regional Ethical Review Board in Stockholm.
While the study was reported to the Danish Health andMedicines
Authority, formal ethics approval was not required due to the
non-interventional design. The study protocol and consent proce-
dures were also reviewed and approved by the clinics.
Sample and inclusion criteria
To be able to capture the full patient pathway, subjects were
enrolled into four mutually exclusive stages of the disease using
a hierarchical approach:
(i) maintenance dialysis: patients currently on dialysis with
or without transplanted kidney
(ii) transplant recipients: patients with a functioning trans-
planted kidney, currently not on dialysis
(iii) CKD stages 4–5: patients not currently on dialysis/no
previous transplant (eGFR <30 mL/min/1.73 m2)
(iv) CKD stages 1–3: patients not currently on dialysis/no
previous transplant (eGFR 30 mL/min/1.73 m2)
The most recent eGFR value, as calculated by each respective lab-
oratory, was used to establish CKD stage at the enrolment date.
Eligible subjects were required to:
• be 18 years of age or older
• have been managed for ADPKD at the clinic during the
past 12 months
• have been diagnosed with ADPKD at least 12 months ago
• have an eGFR laboratory result available in the past 12
months (not applicable if patient was on dialysis)
• not have been involved in an investigational clinical trial
that resulted in a change in the standard of care received in
the past 12 months
• if on maintenance dialysis, have initiated dialysis at least 6
months ago
• if having a working kidney transplant, have had the date of
transplant at least 6 months ago
• provide written informed consent of participation
Study questionnaires
Prior to recruitment of patients all staff at participating clin-
ics received training in study procedures to ensure standardiza-
tion of patient enrolment and data collection. Data were
extracted from medical charts using a case report form (CRF)
and complemented with self-administered questionnaires to
collect PROs.
Patients’ HRQoL was primarily assessed using the EuroQol
EQ-5D-3L due to its applicability across a wide range of health
conditions and common use in health economic evaluations.
Additional information was obtained via the SF-12v2 instru-
ment due to its ability to distinguish between mental and physi-
cal health, while keeping response burden to a minimum. The
EQ-5D-3L comprises five questions and a visual analogue scale
[11]. The five questions correspond to five dimensions (mobi-
lity, self-care, usual activities, pain/discomfort and anxiety/
depression), each of which can take one of three responses (no
problems, some problems and extreme problems). In addition
to a simple descriptive profile it provides a preference-based
summary score of overall HRQoL (index score), with 1 repre-
senting perfect health, 0 representing death and <0 represent-
ing a health state perceived as worse than death. The EQ-5D
also contains a visual analogue scale (VAS) with the end points
labelled best imaginable health state at the top (100) and worst
imaginable health state at the bottom (0).
The SF-12v2 Health Survey is a shorter alternative to the SF-
36v2 Health Survey to measure functional health and well-
being from the patient’s point of view. The instrument provides
a reliable and valid measure of physical and mental health [12].
Two overall scores, the Physical and Mental Composite Score
(PCS and MCS, respectively), in addition to eight health
domains, are derived using norm-based scoring algorithms that
provide means of 50 and standard deviations (SDs) of 10 in the
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|general population. The SF-12 provides estimates of means and
variances for both summary measures and for all scales that are
comparable to the SF-36 [13].
Finally, the Work Productivity and Activity Impairment
General Health (WPAI:GH) questionnaire was used in this
study to estimate the impact of health problems on regular daily
activities [14].
Statistical analyses
Summary statistics were calculated, including means and
SDs for continuous variables and frequency distributions for
categorical variables. EQ-5D index scores were estimated using
UK, Danish and Swedish value sets [15–17]. Norm-based stand-
ardized scores were computed for the SF-12 profile; component
summary scores have a mean of 50 and SD of 10 in the general
1998 US population, as per the SF-12v2 user guide [13]. The
degree (percent) that health affected productivity in regular
daily activities was estimated using question six of the WPAI
questionnaire [14]. Differences across groups were evaluated
using the Kruskal–Wallis and v2/Fisher’s exact tests as appro-
priate. Data management and analysis were performed using
Stata 12.1 (StataCorp LP, College Station, TX, USA).
RESULTS
A total of 266 patients were contacted; of these 243 (91%) pro-
vided consent to participate in the study. The majority of
patients were enrolled in Denmark (n ¼ 118), followed by
Sweden (n ¼ 58), Norway (n ¼ 50) and Finland (n ¼ 17). The
Modification of Diet in Renal Disease (MDRD) equation was
used to estimate GFR in 86% of non-dialysis patients, followed
by the Lund-Malmo¨ equation (8%) and the Chronic Kidney
Disease Epidemiology Collaboration (CKD-EPI) equation
(6%).
Dialysis patients comprised the oldest group, followed by
transplant recipients and non-end-stage renal disease (ESRD)
patients (Table 1). Mean ages ranged from 52 years in patients
with CKD stages 1–3 to 64 years in dialysis patients.
Employment rates were highest in the earlier stages of the dis-
ease. No differences between the disease stages were seen in sex,
body mass index and systolic blood pressure.
Among those on dialysis, 10 patients (16%) had exclusively
been on peritoneal dialysis during the past 12 months, while 49
patients (80%) had only received haemodialysis. Fifteen patients
(25%) had initiated dialysis in the past year (6–12 months prior
to study enrolment date). Among transplant recipients, six
patients (10%) had received the transplant in the past year.
Transplant patients were significantly younger than dialysis
patients at the time of ESRD. Five dialysis patients (8%) had
previously received a kidney transplant.
In general, comorbidities were most common among
patients on dialysis and with CKD stages 4–5 (Table 2). Activity
impairment was highest in dialysis patients (53%). The degree
of impairment was lower among transplant recipients and
patients with CKD stages 4–5 (30 and 29%, respectively) and
lowest in patients with CKD stages 1–3 (17%) (P< 0.0001 for a
difference between groups).
Table 1. Patient characteristics
Patient characteristic CKD 1–3 (n ¼ 64) CKD 4–5 (n ¼ 55) Dialysis (n ¼ 61) Transplant (n ¼ 63) P-value
Sex (female), n (%) 38 (59) 29 (53) 33 (54) 31 (49) 0.7144
Age (years), mean6 SDa 526 13 57 6 12 646 10 596 10 <0.0001
Age (<65 years), n (%) 51 (80) 42 (76) 33 (54) 44 (70) 0.0080
Currently employed (aged <65 years), n (%) 40 (78) 27 (64) 12 (38) 26 (59) <0.0001
eGFR (mL/min/1.73 m2), mean6 SDa 566 21 17 6 7 446 17 <0.0001
BMI (30 kg/m2), n (%) 10 (16) 11 (20) 15 (25) 14 (22) 0.7667
SBP (mmHg), mean6 SDa 1306 15 1356 15 1326 23 1336 15 0.4826
DBP (mmHg), mean6 SDa 826 9 80 6 9 716 13 796 10 <0.0001
Age at ESRD (years), mean6 SDa 596 10 516 11 0.0003
Age at dialysis initiation 596 10 526 11c 0.0078
Age at kidney transplant 506 11
b
526 11 0.6024
P-values calculated with v2 test unless otherwise speciﬁed.
CKD, chronic kidney disease; SD, standard deviation; eGFR, estimated glomerular ﬁltration rate; BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure;
ESRD, end-stage renal disease.
aKruskal–Wallis test; bn ¼ 5; cn ¼ 41.
Table 2. Common comorbidities
Comorbidities, proportion (%) of patients CKD 1–3 (n ¼ 64) CKD 4–5 (n ¼ 55) Dialysis (n ¼ 61) Transplant (n ¼ 63) P-value
Hypertension 44 73 84 60 <0.0001
Secondary hyperparathyroidisma 2 36 79 19 <0.0001
Anaemiaa 6 20 80 11 <0.0001
Non-renal cysts 19 31 39 16 0.0095
Renal paina 25 20 16 8 0.0774
Cardiovascular diseasea 5 9 39 10 <0.0001
Intracranial aneurysma 2 4 10 2 0.0932
CKD, chronic kidney disease.
P-values calculated with v2 test unless otherwise speciﬁed.
aFisher’s exact test.
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Across the study population, a significant proportion of
patients reported (some or extreme) problems with pain, as cap-
tured in the EQ-5D, ranging from 44% in transplant recipients
to 59% in dialysis patients (Table 3). Dialysis patients more fre-
quently reported problems in all five dimensions of the EQ-5D
compared with non-dialysis patients. However, no significant
differences between stages of the disease seemed present for
pain/discomfort and anxiety/depression.
A descriptive representation of the SF-12 scales by stages of
the disease revealed heterogeneity in functional health
(Table 4, Figure 1). Patients with CKD stages 1–3 and trans-
plant recipients showed less variation compared with other
stages of the disease. These patients largely scored above or
around average health (the population norm). Patients with
CKD stages 4–5 generally reported worse physical health than
transplant recipients and patients in earlier stages of CKD,
whereas scores on the mental health domains showed less var-
iation. Dialysis patients tended to have worse functional
health compared with the other stages of ADPKD and showed
the most heterogeneity.
Overall HRQoL, as measured by the EQ-5D and SF-12, was
generally highest in patients with CKD stages 1–3 (Table 5).
Patients with CKD stages 4–5 had numerically lower scores
than transplant recipients on all PROs. Transplant recipients
mostly reported a level of quality of life in between patients with
CKD stages 1–3 and CKD stages 4–5. Group differences in
physical health as captured in the SF-12 PCS largely mirrored
those seen for the EQ-5D index scores and the EQ VAS, while
mean SF-12 MCS scores differed to a lesser degree between dis-
ease stages. The mental health scores were also closer to the gen-
eral population norms compared with the PCS scores. Worst
HRQoL was consistently observed in dialysis patients across
PROs.
DISCUSSION
This cross-sectional study of 243 patients with ADPKD
explored the impact of disease progression on quality of life as
captured by validated PRO measures. Overall HRQoL was gen-
erally highest in patients with CKD stages 1–3, followed by
transplant recipients, patients with CKD stages 4–5 and patients
on dialysis. Progressive disease predominately had an impact on
physical health, whereas mental health showed less variation
between stages of the disease. Dialysis patients consistently
reported the worst HRQoL across measurement scales and had
impaired activity levels at over 50%. The substantial burden
associated with dialysis was also confirmed by high degrees of
comorbidity, including patient-reported overall pain, as meas-
ured by the EQ-5D and SF-12.
Our study showed that patients with CKD stages 4–5 gener-
ally reported worse HRQoL than transplant recipients and
patients in earlier stages of CKD. This was true regardless of
whether the burden was measured using the EQ-5D index score
or the SF-12 physical summary score. The impairment of
patients with CKD stages 4–5 was also confirmed by consider-
ably lower mean renal function, as measured by eGFR, com-
pared with transplant recipients (17 and 44 mL/min/1.73 m2,
respectively). Notably, only around one in four patients with
CKD stages 4–5 reported average or above average health status
(compared with the general population norm) on the two SF-12
domains general health (GH: 25%) and vitality (VT: 27%). Only
dialysis patients scored worse on these health domains (GH:
14%; VT: 19%), while around half of transplant recipients and
patients with CKD stages 1–3 had general health and vitality
scores on a par with the general population (GH: 43 and 54%,
respectively; VT: 49 and 46%, respectively).
Table 3. Problems reported on the ﬁve dimensions of EQ-5D
Problems reported on the EQ-5D,
proportion (%) of patients
CKD 1–3 (n ¼ 64) CKD 4–5 (n ¼ 55) Dialysis (n ¼ 61) Transplant (n ¼ 63) P-value
Mobility 8 20 48 22 <0.0001
Self-care 2 4 18 8 0.0037
Usual activities 16 36 62 32 <0.0001
Pain/discomfort 48 47 59 44 0.2151
Anxiety/depression 30 31 41 22 0.1204
P-values calculated with Fisher’s exact test.
EQ-5D, EuroQol-5 dimension; CKD, chronic kidney disease.
Table 4. Average or above health on the SF-12 proﬁle
Proportion (%) of patients scoring 50
on the SF-12 domains
CKD 1–3 (n ¼ 64) CKD 4–5 (n ¼ 55) Dialysis (n ¼ 61) Transplant (n ¼ 63) P-value
Physical functioning 68 35 12 41 <0.0001
Role physical 62 36 14 40 <0.0001
Bodily pain 60 49 27 44 0.0030
General health 54 25 14 43 <0.0001
Vitality 46 27 19 49 0.0007
Social functioning 68 69 29 63 <0.0001
Role emotional 71 64 36 62 0.0007
Mental health 62 76 51 70 0.0272
SF-12, Short Form-12 Health Survey; CKD, chronic kidney disease.
P-values calculated with v2 test unless otherwise speciﬁed.
All SF-12 scales are standardized to have a mean of 50 and standard deviation of 10 in the US general population (range: 0–100).
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patient-reported pain may indicate that physicians underesti-
mate the impact of renal pain in patients with ADPKD. The
observed higher prevalence of renal pain in earlier stages of
CKD, as captured in the medical charts, could possibly be
explained by differences between patient groups in the record-
ing of symptoms by physicians as well as by coping mechanisms
of patients.
The prevalence of extra-renal cysts in transplant recipients
was relatively low compared with patients with CKD stages 4–5
and dialysis patients. It is possible that this finding could be con-
founded by age or comorbidity levels. Dialysis patients were in
fact older at the time of ESRD compared with transplant recipi-
ents (mean age of 59 and 51 years, respectively). Furthermore,
patients burdened by extra-renal cysts may be less likely to
become transplant candidates.
Previous studies of patients with ADPKD have mainly
focused on later stages of the disease and results on the link
between progressive disease and quality of life have been con-
flicting [7–10]. The findings of our study are consistent with a
recent UK study, which showed a clinically relevant decline in
quality of life scores across eGFR groups [as defined by the min-
imal clinically important difference (MCID) in the SF-36 of at
least 3–5 points] [10]. Using the same MCID definition, since
the SF-12 provides comparable estimates to the SF-36 [13], the
PCS scores reported in our study were considerably lower com-
pared with the general population norm for all levels of the dis-
ease except for CKD stages 1–3. Specially, the difference of 8
FIGURE 1: Norm-based scoring of the Short Form-12 Health Survey (SF-12) proﬁle. All SF-12 scales are standardized to have a mean of 50
and standard deviation of 10 in the general 1998 US population (range: 0–100). Boxes extend from the 25th to 75th percentiles with the median
highlighted; whiskers (vertical lines) extend 1.5 times the interquartile range. PF, physical functioning; RP, role physical; BP, bodily pain; GH,
general health; VT, vitality; SF, social functioning; RE, role emotional; MH, mental health.
Table 5. Overall HRQoL
HRQoL estimates, mean6 SD CKD 1–3 (n ¼ 64) CKD 4–5 (n ¼ 55) Dialysis (n ¼ 61) Transplant (n ¼ 63) P-value
EQ-5D index (UK)
a
0.86 6 0.16 0.79 6 0.23 0.686 0.30 0.82 6 0.21 0.0036
EQ-5D index (Denmark)
a
0.87 6 0.14 0.82 6 0.18 0.736 0.22 0.85 6 0.16 0.0025
EQ-5D index (Sweden)
a
0.91 6 0.08 0.88 6 0.11 0.816 0.13 0.89 6 0.10 <0.0001
EQ VAS score
b
81.716 16.63 70.436 22.70 60.146 20.84 76.746 16.88 <0.0001
SF-12 PCSc 51.186 7.50 42.986 10.34 34.916 11.12 44.986 11.06 <0.0001
SF-12 MCSc 50.466 9.59 52.666 8.37 47.006 9.04 52.736 8.95 0.0007
P-values calculated with Kruskal–Wallis test; utility values (EQ-5D) were estimated using national value sets for the UK, Denmark and Sweden, respectively; SF-12 component summary
scores were norm-based, computed to have a mean of 50 and standard deviation of 10 in the general 1998 US population.
HRQoL, health-related quality of life; SD, standard deviation; CKD, chronic kidney disease; VAS, visual analogue scale; EQ-5D, EuroQol-5 dimension; SF-12, Short Form-12 Health
Survey; PCS, Physical Component Summary; MCS, Mental Component Summary.
aCKD stages 1–3: n ¼ 63, CKD stages 4–5: n ¼ 54, dialysis patients: n ¼ 56, transplant recipients: n ¼ 61.
bCKD stages 1–3: n ¼ 61, CKD stages 4–5: n ¼ 53, dialysis patients: n ¼ 59, transplant recipients: n ¼ 61.
cCKD stages 1–3: n ¼ 60, CKD stages 4–5: n ¼ 55, dialysis patients: n ¼ 56, transplant recipients: n ¼ 63.
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points between CKD stages 1–3 and 4–5 confirms the consider-
able loss in quality of life prior to ESRD.
Generic tools such as the SF-36, and by extension the SF-12,
have been criticized in the past for not being able to detect clini-
cally important changes in quality of life among patients with
ADPKD [7, 10]. While significant differences were detected on
the SF-12 PCS in our study, functional mental health as captured
by the MCS was similar to the general population for all stages of
ADPKD. These results are in line with other studies that did not
detect a significant association between mental health and stages
of the disease or a difference compared with the general popula-
tion [7, 8, 10]. There are however ongoing initiatives to address
this issue by establishing a new disease-specific instrument that
captures the impact of coping with the diagnosis of a genetic dis-
ease and the associated psychological burden [10].
Some other limitations should also be noted. As with any
observational study, selection bias may be an issue as predomi-
nantly patients seeking healthcare were included. Furthermore,
we could not use kidney size as a proxy for disease severity since
such data are not routinely recorded in clinical practice; in our
population only 113 (47%) patients had an available kidney
length measure. Finally, a disadvantage of the norm-based scor-
ing of the SF-12 is that the mean health in all countries is not
50. In Sweden and Denmark the mean MCS SF-12 scores have
been found to be nearly three points higher than in the USA
[13], which may result in an underestimation of the burden of
disease in our study.
Our study is, to our knowledge, the first to present HRQoL in
a population stratified by all stages of the disease, from early
CKD to dialysis and transplantation. The study also provides the
first ever Nordic EQ-5D results in ADPKD. Further strengths of
this study include the high response rate and the enrolment of
patients with physician-confirmed diagnosis of ADPKD.
To summarize, we demonstrated an association between dis-
ease progression and reduced physical health. As expected, dialy-
sis patients reported the lowest quality of life, possibly due to the
substantial burden of dialysis itself. Furthermore, a considerable
loss in quality of life was observed prior to ESRD as patients
progress to CKD stages 4–5. These findings warrant the intro-
duction of measures in clinical practice to improve quality of life
in ADPKD patients. The value of early treatment interventions
that can delay progression of the disease should be considered.
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